Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in...

HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntingtons disease Clinical Advisory Board formed to… [+11329 chars]

Related Posts

About FHMnews

What is FHMnews?

FHMnews is the result of a rebellion that transcended frustration. Look around you. As PK puts it, the people in this circle think one thing, say another, and do another. We shook up all three, confined within one circle, and decided to write as they think and speak. News, views, and everything beyond.

FHMnews is the country's first "new age" English news website. It's modern in its language, attitude, and news standards. It features selected news stories from the day, but with 360-degree coverage. It offers a complete report and analysis of each story, along with additional features like quizzes, polls, memes, and videos.

FHMnews Ltd.

E-43, Phase 8
Sahibzada Ajit Singh Nagar,
Punjab, 160071

Get In Touch With Us

© Copyright FHMnews
Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board - FHMnews